Leerink Partners Begins Coverage on Aktis Oncology (NASDAQ:AKTS)

Equities researchers at Leerink Partners assumed coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a report released on Tuesday, Marketbeat.com reports. The firm set an “outperform” rating and a $31.00 price target on the technology company’s stock. Leerink Partners’ price objective indicates a potential upside of 55.62% from the stock’s previous close.

Several other equities analysts have also issued reports on the stock. TD Cowen initiated coverage on shares of Aktis Oncology in a report on Tuesday. They issued a “buy” rating on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $31.67.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $19.92 on Tuesday. Aktis Oncology has a 52-week low of $18.02 and a 52-week high of $29.16.

Insider Activity at Aktis Oncology

In related news, Director Helen Susan Kim purchased 835,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the director owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the transaction, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 over the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Key Aktis Oncology News

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Bank of America initiated coverage with a “buy” rating and a $34.00 price target (implies ~71% upside vs. the referenced price), providing a sizeable bullish catalyst for AKTS.
• Positive Sentiment: Leerink Partners started coverage with an “outperform” rating and a $31.00 target (roughly 56% upside), adding another institutional endorsement that could attract investor interest. Article Title
• Positive Sentiment: JPMorgan initiated with an “overweight” rating and a $30.00 price target (~51% upside), adding further sell‑side conviction that AKTS’s pipeline and platform could support higher valuations. Article Title
• Positive Sentiment: TD Cowen (covered in TipRanks and The Fly writeups) initiated coverage with a Buy rating and highlighted Aktis’s differentiated miniprotein radiopharma platform and multi‑billion dollar sales potential — a thematic, research‑driven positive for investor sentiment. Article Title Article Title
• Neutral Sentiment: A short‑interest report in the record shows essentially zero reported short interest (entries list 0 shares and an uninformative NaN change), so short covering or aggressive short selling does not appear to explain today’s move.
• Negative Sentiment: Despite the bullish analyst initiations, the stock is trading down on the day with volume slightly below its average — a sign of short‑term profit taking or sector/market weakness outweighing the positive analyst news in the near term.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.